VistaGen Therapeutics Net Income
| VTGN Stock | USD 0.51 0.04 7.27% |
As of the 15th of February 2026, VistaGen Therapeutics has the Coefficient Of Variation of (681.07), variance of 132.25, and Risk Adjusted Performance of (0.11). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of VistaGen Therapeutics, as well as the relationship between them.
VistaGen Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 76.82 | Revenue | Earnings Share (1.92) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -46.3 M | -44 M | |
| Net Loss | -46.3 M | -48.6 M | |
| Net Loss | -53.3 M | -50.7 M | |
| Net Loss | (0.46) | (0.48) | |
| Net Income Per E B T | 1.00 | 0.80 |
VistaGen | Net Income | Build AI portfolio with VistaGen Stock |
Evaluating VistaGen Therapeutics's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into VistaGen Therapeutics's fundamental strength.
Latest VistaGen Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of VistaGen Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in VistaGen Therapeutics financial statement analysis. It represents the amount of money remaining after all of VistaGen Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is VistaGen Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in VistaGen Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (51.42 M) | 10 Years Trend |
|
Net Income |
| Timeline |
VistaGen Net Income Regression Statistics
| Arithmetic Mean | (26,770,756) | |
| Coefficient Of Variation | (69.91) | |
| Mean Deviation | 16,218,106 | |
| Median | (20,774,000) | |
| Standard Deviation | 18,714,243 | |
| Sample Variance | 350.2T | |
| Range | 59.2M | |
| R-Value | (0.77) | |
| Mean Square Error | 154.4T | |
| R-Squared | 0.59 | |
| Significance | 0.0003 | |
| Slope | (2,838,593) | |
| Total Sum of Squares | 5603.6T |
VistaGen Net Income History
Other Fundumenentals of VistaGen Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
VistaGen Therapeutics Net Income component correlations
VistaGen Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for VistaGen Therapeutics is extremely important. It helps to project a fair market value of VistaGen Stock properly, considering its historical fundamentals such as Net Income. Since VistaGen Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of VistaGen Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of VistaGen Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could VistaGen diversify its offerings? Factors like these will boost the valuation of VistaGen Therapeutics. If investors know VistaGen will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every VistaGen Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.92) | Revenue Per Share | Quarterly Revenue Growth 0.41 | Return On Assets | Return On Equity |
Investors evaluate VistaGen Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating VistaGen Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause VistaGen Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between VistaGen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VistaGen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, VistaGen Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
VistaGen Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to VistaGen Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of VistaGen Therapeutics.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in VistaGen Therapeutics on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding VistaGen Therapeutics or generate 0.0% return on investment in VistaGen Therapeutics over 90 days. VistaGen Therapeutics is related to or competes with Spero Therapeutics, Seer, Seres Therapeutics, Opus Genetics, Cognition Therapeutics, TuHURA Biosciences, and Agenus. VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing vario... More
VistaGen Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure VistaGen Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess VistaGen Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.15) | |||
| Maximum Drawdown | 96.59 | |||
| Value At Risk | (12.80) | |||
| Potential Upside | 7.93 |
VistaGen Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for VistaGen Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as VistaGen Therapeutics' standard deviation. In reality, there are many statistical measures that can use VistaGen Therapeutics historical prices to predict the future VistaGen Therapeutics' volatility.| Risk Adjusted Performance | (0.11) | |||
| Jensen Alpha | (1.79) | |||
| Total Risk Alpha | (2.55) | |||
| Treynor Ratio | (1.12) |
VistaGen Therapeutics February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (1.11) | |||
| Mean Deviation | 5.68 | |||
| Coefficient Of Variation | (681.07) | |||
| Standard Deviation | 11.5 | |||
| Variance | 132.25 | |||
| Information Ratio | (0.15) | |||
| Jensen Alpha | (1.79) | |||
| Total Risk Alpha | (2.55) | |||
| Treynor Ratio | (1.12) | |||
| Maximum Drawdown | 96.59 | |||
| Value At Risk | (12.80) | |||
| Potential Upside | 7.93 | |||
| Skewness | (4.99) | |||
| Kurtosis | 34.01 |
VistaGen Therapeutics Backtested Returns
VistaGen Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.17, which indicates the firm had a -0.17 % return per unit of risk over the last 3 months. VistaGen Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate VistaGen Therapeutics' Variance of 132.25, risk adjusted performance of (0.11), and Coefficient Of Variation of (681.07) to confirm the risk estimate we provide. The entity has a beta of 1.52, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, VistaGen Therapeutics will likely underperform. At this point, VistaGen Therapeutics has a negative expected return of -1.99%. Please make sure to validate VistaGen Therapeutics' value at risk, daily balance of power, as well as the relationship between the Daily Balance Of Power and price action indicator , to decide if VistaGen Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.78 |
Good predictability
VistaGen Therapeutics has good predictability. Overlapping area represents the amount of predictability between VistaGen Therapeutics time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of VistaGen Therapeutics price movement. The serial correlation of 0.78 indicates that around 78.0% of current VistaGen Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.78 | |
| Spearman Rank Test | 0.69 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
VistaGen Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, VistaGen Therapeutics reported net income of (51.42 Million). This is 115.07% lower than that of the Biotechnology sector and 173.41% lower than that of the Health Care industry. The net income for all United States stocks is 109.01% higher than that of the company.
VistaGen Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses VistaGen Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of VistaGen Therapeutics could also be used in its relative valuation, which is a method of valuing VistaGen Therapeutics by comparing valuation metrics of similar companies.VistaGen Therapeutics is currently under evaluation in net income category among its peers.
VistaGen Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of VistaGen Therapeutics from analyzing VistaGen Therapeutics' financial statements. These drivers represent accounts that assess VistaGen Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of VistaGen Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 19.3M | 183.5M | 245.5M | 25.1M | 22.5M | 21.4M | |
| Enterprise Value | 22.0M | 84.1M | 180.4M | 11.1M | 10.0M | 9.5M |
VistaGen Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in VistaGen Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of VistaGen Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing VistaGen Therapeutics' value.| Shares | Geode Capital Management, Llc | 2025-06-30 | 272.9 K | Almitas Capital Llc | 2025-06-30 | 261.4 K | Advisorshares Investments, Llc | 2025-06-30 | 203.1 K | Boothbay Fund Management, Llc | 2025-06-30 | 177.9 K | Bml Capital Management Llc | 2025-06-30 | 150 K | Susquehanna International Group, Llp | 2025-06-30 | 115.4 K | State Street Corp | 2025-06-30 | 96.9 K | Jane Street Group Llc | 2025-06-30 | 95.1 K | Two Sigma Investments Llc | 2025-06-30 | 89.5 K | Tcg Crossover Management, Llc | 2025-06-30 | 2.7 M | Stempoint Capital Lp | 2025-06-30 | 2.4 M |
VistaGen Fundamentals
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.45 | ||||
| Operating Margin | (77.72) % | ||||
| Current Valuation | (55.29 M) | ||||
| Shares Outstanding | 39.5 M | ||||
| Shares Owned By Insiders | 0.26 % | ||||
| Shares Owned By Institutions | 51.35 % | ||||
| Number Of Shares Shorted | 2.04 M | ||||
| Price To Earning | (0.66) X | ||||
| Price To Book | 0.30 X | ||||
| Price To Sales | 27.70 X | ||||
| Revenue | 486 K | ||||
| Gross Profit | 721 K | ||||
| EBITDA | (55.34 M) | ||||
| Net Income | (51.42 M) | ||||
| Cash And Equivalents | 51.99 M | ||||
| Cash Per Share | 0.25 X | ||||
| Total Debt | 1.51 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 6.16 X | ||||
| Book Value Per Share | 1.71 X | ||||
| Cash Flow From Operations | (42.1 M) | ||||
| Short Ratio | 1.46 X | ||||
| Earnings Per Share | (1.92) X | ||||
| Target Price | 0.97 | ||||
| Number Of Employees | 59 | ||||
| Beta | 0.3 | ||||
| Market Capitalization | 19.97 M | ||||
| Total Asset | 84.34 M | ||||
| Retained Earnings | (407.63 M) | ||||
| Working Capital | 69.46 M | ||||
| Current Asset | 6.91 M | ||||
| Current Liabilities | 1.8 M | ||||
| Net Asset | 84.34 M |
About VistaGen Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze VistaGen Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of VistaGen Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of VistaGen Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with VistaGen Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if VistaGen Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in VistaGen Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against VistaGen Stock
| 0.81 | DRTS | Alpha Tau Medical | PairCorr |
| 0.74 | EQ | Equillium | PairCorr |
| 0.69 | GXEA | Galapagos NV | PairCorr |
| 0.68 | VERA | Vera Therapeutics Sell-off Trend | PairCorr |
| 0.64 | 6C1 | CytomX Therapeutics | PairCorr |
The ability to find closely correlated positions to VistaGen Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace VistaGen Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back VistaGen Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling VistaGen Therapeutics to buy it.
The correlation of VistaGen Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as VistaGen Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if VistaGen Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for VistaGen Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Will Biotechnology sector continue expanding? Could VistaGen diversify its offerings? Factors like these will boost the valuation of VistaGen Therapeutics. If investors know VistaGen will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every VistaGen Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.92) | Revenue Per Share | Quarterly Revenue Growth 0.41 | Return On Assets | Return On Equity |
Investors evaluate VistaGen Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating VistaGen Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause VistaGen Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between VistaGen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VistaGen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, VistaGen Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.